| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000012668 |
| Receipt No. | R000014812 |
| Official scientific title of the study | Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure |
| Date of disclosure of the study information | 2013/12/25 |
| Last modified on | 2017/06/29 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | Efficacy and safety of simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure | |
| Title of the study (Brief title) | Simeprevir plus pegylated intereferon combination therapy for HCV genotype 1 patients with chronic renal failure | |
| Region |
|
|
| Condition | ||
| Condition | chronic infection with hepatitis C virus | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Investigating sustained virological response rate (the rate of undetectable HCV RNA at end of treatment and at 24 weeks after completion of treatment) of Simeprevir plus Peg-IFN combination therapy in HCV genotype 1 patients with chronic renal failure. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | - Investigating sustained virological response rate (the rate of undetectable HCV RNA at end of treatment and at 24 weeks after completion of treatment) of Simeprevir plus Peg-IFN combination therapy in HCV genotype 1 patients with chronic renal failure.
- Investigating the factors for sustained virological response. |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Historical |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Simeprevir plus Peg-IFN combination therapy | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Hemodialysis patients
2) Patients with chronic infection with hepatitis C virus genotype 1 and more than 5 log IU/ml |
|||
| Key exclusion criteria | 1) Patients with co-infection with hepatitis B virus or human immunodeficiency virus or alcoholic liver disorder or autoimmune hepatitis.
2) Patients with uncompensated cirrhosis or hepatic failure 3) Patients with multiple organ failure or immunological deficiency 4) Patients with severe depression or past history of psychiatric disorder 5) Patients in pregnancy or lactating or patients who expect to become pregnant |
|||
| Target sample size | 45 | |||
| Research contact person | |
| Name of lead principal investigator | Tetsuo Takehara |
| Organization | Osaka University Graduate school of Medicine |
| Division name | Department of Gastroenterology and Hepatology |
| Address | Yamadaoka 2-2, Suita, Osaka, Japan |
| TEL | 06-6879-3621 |
| takehara@gh.med.osaka-u.ac.jp | |
| Public contact | |
| Name of contact person | Naoki Hiramatsu |
| Organization | Osaka University Graduate school of Medicine |
| Division name | Gastroenterology and Hepatology |
| Address | Yamadaoka 2-2, Suita, Osaka, Japan |
| TEL | 06-6879-3621 |
| Homepage URL | |
| hiramatsu@gh.med.osaka-u.ac.jp | |
| Sponsor | |
| Institute | Osaka University Graduate school of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Osaka University Graduate school of Medicine |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000014812 |